Education
About Us
Working with TipRanks
Follow Us
Doximity (DOCS)
NYSE:DOCS
DOCS Analyst Ratings
Moderate Buy
9 Buy
7 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
DOCS Stock 12 Month Forecast
Average Price Target
$70.00
▼(-2.76% Downside)
| Highest Price Target$80.00 | Average Price Target$70.00 | Lowest Price Target$59.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Raymond James
$75
Buy
4.18%
Upside
Reiterated
10/03/25
Bank of America Securities
$75
Hold
4.18%
Upside
Reiterated
10/03/25
Goldman Sachs
$57→$64
Sell
-11.10%
Downside
Downgraded
10/01/25
Canaccord Genuity
$59→$67
Hold
-6.93%
Downside
Reiterated
09/17/25
TR | OpenAI - 4o
$71
Buy
-1.38%
Downside
Reiterated
09/12/25
AI Generated ArticleAI Generated Article
Robert W. Baird
$75→$80
Buy
11.13%
Upside
Reiterated
09/11/25
Leerink Partners
$79
Buy
9.74%
Upside
Reiterated
08/15/25
Doximity's Strong Market Position and AI-Driven Growth Reinforce Buy RatingWe spent some time with DOCS management, including CFO Anna Bryson and VP of IR and RevOps Perry Gold as part of a set of meetings with investors in Boston. The meetings followed a decidedly positive FY1Q'26 results that showed widespread strength across the overall business/customer base. Our time with management confirmed our underlying view of DOCS' continually expanding moat, using a robust platform of solutions (discussed below) to drive expanding member engagement. And more engagement = better ROI for DOCS' core biopharma customer base. We continue to see robust profit growth/cash flow generation for DOCS and reiterate our Outperform rating.
Piper Sandler
$65→$69
Buy
-4.15%
Downside
Reiterated
08/08/25
J.P. Morgan
$60→$62
Hold
-13.88%
Downside
Reiterated
08/08/25
Needham
$75
Buy
4.18%
Upside
Reiterated
08/08/25
Morgan Stanley
$60→$62
Hold
-13.88%
Downside
Reiterated
08/08/25
Mizuho Securities
$50→$59
Hold
-18.04%
Downside
Reiterated
08/08/25
Wells Fargo
$62→$65
Hold
-9.71%
Downside
Reiterated
08/08/25
Evercore ISI
$70→$75
Buy
4.18%
Upside
Reiterated
08/08/25
Truist Financial
$61→$62
Hold
-13.88%
Downside
Reiterated
08/08/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Raymond James
$75
Buy
4.18%
Upside
Reiterated
10/03/25
Bank of America Securities
$75
Hold
4.18%
Upside
Reiterated
10/03/25
Goldman Sachs
$57→$64
Sell
-11.10%
Downside
Downgraded
10/01/25
Canaccord Genuity
$59→$67
Hold
-6.93%
Downside
Reiterated
09/17/25
TR | OpenAI - 4o
$71
Buy
-1.38%
Downside
Reiterated
09/12/25
AI Generated ArticleAI Generated Article
Robert W. Baird
$75→$80
Buy
11.13%
Upside
Reiterated
09/11/25
Leerink Partners
$79
Buy
9.74%
Upside
Reiterated
08/15/25
Doximity's Strong Market Position and AI-Driven Growth Reinforce Buy RatingWe spent some time with DOCS management, including CFO Anna Bryson and VP of IR and RevOps Perry Gold as part of a set of meetings with investors in Boston. The meetings followed a decidedly positive FY1Q'26 results that showed widespread strength across the overall business/customer base. Our time with management confirmed our underlying view of DOCS' continually expanding moat, using a robust platform of solutions (discussed below) to drive expanding member engagement. And more engagement = better ROI for DOCS' core biopharma customer base. We continue to see robust profit growth/cash flow generation for DOCS and reiterate our Outperform rating.
Piper Sandler
$65→$69
Buy
-4.15%
Downside
Reiterated
08/08/25
J.P. Morgan
$60→$62
Hold
-13.88%
Downside
Reiterated
08/08/25
Needham
$75
Buy
4.18%
Upside
Reiterated
08/08/25
Morgan Stanley
$60→$62
Hold
-13.88%
Downside
Reiterated
08/08/25
Mizuho Securities
$50→$59
Hold
-18.04%
Downside
Reiterated
08/08/25
Wells Fargo
$62→$65
Hold
-9.71%
Downside
Reiterated
08/08/25
Evercore ISI
$70→$75
Buy
4.18%
Upside
Reiterated
08/08/25
Truist Financial
$61→$62
Hold
-13.88%
Downside
Reiterated
08/08/25
Best Analysts Covering Doximity
1 Month
xxx
Success Rate
7/11 ratings generated profit
Average Return
+6.15%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +6.15% per trade.
3 Months
xxx
Success Rate
7/11 ratings generated profit
Average Return
-0.10%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of -0.10% per trade.
1 Year
Success Rate
5/11 ratings generated profit
Average Return
-8.86%
reiterated a buy rating yesterday
Copying Brian Peterson's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -8.86% per trade.
2 Years
xxx
Success Rate
8/9 ratings generated profit
Average Return
+26.19%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +26.19% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
DOCS Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
1
1
1
0
0
Buy
15
14
20
19
17
Hold
19
20
18
16
12
Sell
0
0
0
0
1
Strong Sell
0
0
0
0
0
total
35
35
39
35
30
Each month's total comprises the sum of three months' worth of ratings.
DOCS Financial Forecast
DOCS Stock Forecast FAQ
What is DOCS’s average 12-month price target, according to analysts?
Based on analyst ratings, Doximity’s 12-month average price target is 70.00.
What is DOCS’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DOCS, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is DOCS a Buy, Sell or Hold?
Doximity has a consensus rating of Moderate Buy which is based on 9 buy ratings, 7 hold ratings and 1 sell ratings.
What is Doximity’s price target?
The average price target for Doximity is 70.00. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $59.00. The average price target represents -2.76% Decrease from the current price of $71.99.
The highest analyst price target is $80.00 ,the lowest forecast is $59.00. The average price target represents -2.76% Decrease from the current price of $71.99.
What do analysts say about Doximity?
Doximity’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of DOCS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.